Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "ITU"

1664 News Found

Infinitus launches MCP server to bring standardized AI interoperability to healthcare
Digitisation | September 29, 2025

Infinitus launches MCP server to bring standardized AI interoperability to healthcare

New infrastructure makes it possible for healthcare organizations to integrate AI agents seamlessly into critical workflows like benefit verification and prior authorization


Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad
News | August 12, 2025

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

AINU is set to accelerate its expansion footprint, enhance operational capabilities


WHO, ITU, and WIPO release new report on AI use in traditional medicine
News | July 15, 2025

WHO, ITU, and WIPO release new report on AI use in traditional medicine

The global TCIM market is expected to reach nearly US$ 600 billion by 2025


Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer
Clinical Trials | July 01, 2025

Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options


Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC
News | June 07, 2025

Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC

If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference


Merck’s MK-1084 shows antitumor activity in Phase 1 trial of patients with advanced colorectal cancer
News | May 31, 2025

Merck’s MK-1084 shows antitumor activity in Phase 1 trial of patients with advanced colorectal cancer

Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations


Merck withdraws Biologics License Application for Patritumab Deruxtecan
Drug Approval | May 30, 2025

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance


Zydus Lifesciences to acquire 85.6 % stake in Amplitude Surgical
News | April 26, 2025

Zydus Lifesciences to acquire 85.6 % stake in Amplitude Surgical

The closing of the Block Acquisition is now expected to be completed by Q3 2025